Selected Kinase Inhibitors/Antacids Interactions

This information is generalized and not intended as specific medical advice. Consult your healthcare professional before taking or discontinuing any drug or commencing any course of treatment.

Medical warning:

Moderate. These medicines may cause some risk when taken together. Contact your healthcare professional (e.g. doctor or pharmacist) for more information.

How the interaction occurs:

The pH of your GI tract needs to be acidic for your medicine to dissolve and be absorbed. Antacids change the pH (acidity) of your GI tract.

What might happen:

Taking your medicine at the same time as an antacid may decrease the amount of medicine in your blood and it may not work as well.

What you should do about this interaction:

Let your healthcare professionals (e.g. doctor or pharmacist) know that you are taking these medicines together. Your doctor may instruct you to take antacids instead of other medicines for heartburn/ulcers such as H-2 blockers (e.g. cimetidine, famotidine, nizatidine, ranitidine) or proton-pump inhibitors (e.g. esomeprazole, lansoprazole, omeprazole, pantoprazole, rabeprazole).If you need to use an antacid, separate the times you take your cancer medicine and your antacid by several hours, but at least 2 hours for bosutinib, dasatinib, nilotinib, or pexidartinib, 6 hours for gefitinib, and 3 hours for neratinib.If you have questions about how to schedule your medicines, ask your pharmacist.Your healthcare professionals may already be aware of this interaction and may be monitoring you for it. Do not start, stop, or change the dosage of any medicine before checking with them first.

  • 1.Bosulif (bosutinib) US prescribing information. Pfizer Inc. November 18, 2018.
  • 2.Sprycel (dasatinib) US prescribing information. Bristol-Myers Squibb Company November 19, 2017.
  • 3.Tarceva (erlotinib) US prescribing information. Genentech, Inc. October, 2016.
  • 4.Iressa (gefitinib) US prescribing information. AstraZeneca March 6, 2012. 5.Nerlynx (neratinib) US prescribing information. Puma Biotechnology, Inc. June, 2018.
  • 5.Tasigna (nilotinib) US prescribing information. Novartis Pharmaceuticals Corporation March, 2018.
  • 6.Votrient (pazopanib) US prescribing information. GlaxoSmithKline May, 2017.
  • 7.Turalio (pexidartinib) US prescribing information. Daiichi Sankyo, Inc. August, 2019.

Selected from data included with permission and copyrighted by First Databank, Inc. This copyrighted material has been downloaded from a licensed data provider and is not for distribution, except as may be authorized by the applicable terms of use.

CONDITIONS OF USE: The information in this database is intended to supplement, not substitute for, the expertise and judgment of healthcare professionals. The information is not intended to cover all possible uses, directions, precautions, drug interactions or adverse effects, nor should it be construed to indicate that use of a particular drug is safe, appropriate or effective for you or anyone else. A healthcare professional should be consulted before taking any drug, changing any diet or commencing or discontinuing any course of treatment.